Hikal Ltd

Stage 3 · Topping · week 2

As of 16 Oct 2026, Hikal is in Stage 3 — topping, where an uptrend loses steam, in week 2 (since 8 Oct 2026). It closed at ₹216, 15.7% below its 52-week high and above its 200-day average, which is falling. In Health Care, 40.6% of stocks are in Stage 2.

Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences… More about the company

₹215.6
-0.38% today
₹2,659 Cr · Small cap
Market Neutral — FadingHealth Care 40.6% in Stage 2-7.4 pts / 20dPharmaceuticals 50.4%-2.5 pts

Pro read

Pro

Our read

Topping — the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is HIKAL early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-15.7%
₹147.1 lo₹255.9 hi
15.7% below 52W high — weakening from peak
Stock is rolling over from its 52W high. Stage 3 distribution — new longs are high risk here.
Stage Maturity
Week 2
1w13w26w
Week 2 — early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
5.1%
200 DMA: ₹205.3 · sloping down
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.11x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution — institutions are exiting. A clear warning to avoid new longs.
Trend Health
↓
MA20 rolling over · -3.2% vs MA50 -1.5%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-3.9%
3M
-5.8%
6M
+14.5%
YTD
-9.9%
1Y
-13.8%
Sector
Health Care
↓ Peaking
Stage 2%
40.6%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
Sector has 67 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
50.4%
20d Δ
-2.5pp
1M return
-2.3%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Industry has 57 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Stage Cycle Timeline2023-07-20 → 2026-10-16
S4 21w
S2 37w
S4 46w
2023-07-202026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 2w → S4 21w → S1 6w → S2 3w → S1 1w → S4 7w → S1 3w → S2 37w → S3 8w → S2 11w → S3 3w → S4 46w → S1 10w → S2 10w → S3 1w current
Total tracked: 169 weeks across 15 stage runs.
Scan Membership
Prop Scan
Latest: 2026-10-07
Breakout Watch
Latest: 2026-07-29
13 appearances in last 60 days. First seen: 2024-02-12.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding — staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-16S3
Wk 2 · Vol 0.11x
2026-10-15S3
Wk 2 · Vol 0.08x
2026-10-14S3
Wk 1 · Vol 0.15x
2026-10-13S3
Wk 1 · Vol 0.14x
2026-10-12S3
Wk 1 · Vol 0.21x
2026-10-09S3
Wk 1 · Vol 0.17x
2026-10-08S32→3
Wk 1 · Vol 0.29x
2026-10-07S2
Wk 10 · Vol 0.17x
2026-10-06S2
Wk 10 · Vol 0.35x
2026-10-05S2
Wk 10 · Vol 0.14x
2026-10-01S2
Wk 10 · Vol 0.54x
2026-09-30S2
Wk 9 · Vol 0.24x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹218.8
200 DMA
₹205.3
52W High
₹255.9
52W Low
₹147.1
5D Low
₹212.8
Resistance levels (recent highs)
20d High
₹232.4
60d High
₹246
120d High
₹246
250d High
₹255.9
Next resistance
+7.8%
to 20d High
Ask the Market AI about HIKALAsk →
Earnings Growth (YoY)
+68.3%
Revenue +37.3%
Dividend Yield
0.46%
P/B 2.2
About this companyHealth Care· Pharmaceuticals

Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals indusries. It operates through two segments, Pharmaceuticals and Crop Protection. The company also manufactures pesticides and herbicides, which include diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. In addition, it offers solutions in contract research, custom synthesis, and custom manufacturing of intermediates and active ingredients. Further, the company provides anti-convulsant, anti-inflammatory, analgesic, Anti-parasitic, anti-lipemic, anti-histaminic, anti-depressant, anti-psychotic, anti-emetic, anti-diabetic, anti-thrombotic, Anti-viral, anti-hypertensive, and Haemorheologic; animal health products, such as anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, insecticide, and NSAID; and specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. The company also exports its products. It operates in India, the United States, Canada, Europe, South East Asia, and internationally. The company was formerly known as Hikal Chemical Industries Ltd. and changed its name to Hikal Limited in April 2000. Hikal Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.